Ceramides Mixture

CAS No. 100403-19-8

Ceramides Mixture( —— )

Catalog No. M22936 CAS No. 100403-19-8

Ceramides Mixture, an endogenous ceramide, consists of hydroxy and non-hydroxy fatty acid-containing ceramides. It is involved in the regulation of cell cycle arrest, growth inhibition, and modulation of telomerase activity.Endogenous Ceramides inhibits mRNA synthesis of telomerase reverse transcriptase and telomerase activity via inactivation of the c-Myc transcription factor in the A549 human lung adenocarcinoma cell line.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 41 In Stock
5MG 67 In Stock
10MG 97 In Stock
25MG 160 In Stock
50MG 245 In Stock
100MG 357 In Stock
500MG 842 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Ceramides Mixture
  • Note
    Research use only, not for human use.
  • Brief Description
    Ceramides Mixture, an endogenous ceramide, consists of hydroxy and non-hydroxy fatty acid-containing ceramides. It is involved in the regulation of cell cycle arrest, growth inhibition, and modulation of telomerase activity.Endogenous Ceramides inhibits mRNA synthesis of telomerase reverse transcriptase and telomerase activity via inactivation of the c-Myc transcription factor in the A549 human lung adenocarcinoma cell line.
  • Description
    Ceramides Mixture, an endogenous ceramide, consists of hydroxy and non-hydroxy fatty acid-containing ceramides. It is involved in the regulation of cell cycle arrest, growth inhibition, and modulation of telomerase activity.Endogenous Ceramides inhibits mRNA synthesis of telomerase reverse transcriptase and telomerase activity via inactivation of the c-Myc transcription factor in the A549 human lung adenocarcinoma cell line. The sustained generation of long-chain endogenous ceramide requires the biochemical recycling of the sphingosine backbone of C6-ceramide, which involves deacylation and reacylation of ceramide for the generation of endogenous long-chain ceramide, most likely by CoA-dependent ceramide synthase, which is inhibited by fumonisin B1. In A549 cells the generation of long-chain endogenous ceramide mediates the effects of exogenous C6-ceramide on growth inhibition, cell cycle arrest, and the modulation of telomerase activity.
  • In Vitro
    Endogenous Ceramides (generated in response to bacterial sphingomyelinase overexpression or daunorubicin treatment) inhibits mRNA synthesis of telomerase reverse transcriptase and telomerase activity via inactivation of c-Myc transcription factor in the A549 human lung adenocarcinoma cell line.The sustained generation of long chain endogenous ceramide requires the biochemical recycling of the sphingosine backbone of C6-ceramide, which involves deacylation and reacylation of ceramide for the generation of endogenous long chain ceramide (mainly C16:0- and C24:1-Ceramides), most likely by CoA-dependent ceramide synthase, which is inhibited by fumonisin B1. In A549 cells the generation of long chain endogenous ceramide mediates the effects of exogenous C6-ceramide on growth inhibition, cell cycle arrest, and the modulation of telomerase activity.
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Telomerase
  • Recptor
    Telomerase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    100403-19-8
  • Formula Weight
    582
  • Molecular Formula
    C36H71NO4
  • Purity
    >98% (HPLC)
  • Solubility
    Methanol:25 mg/mL (Need ultrasonic)
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ogretmen B, et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J Biol Chem. 2002 Apr 12;277(15):12960-9.
molnova catalog
related products
  • 360A

    360A is a stabilizing G-Quadruplex ligand and also inhibits telomerase activity for telomerase in TRAP-G4 assay(IC50 : 300 nM).

  • Braco-19

    Braco-19 is a telomerase/telomere inhibitor and an inhibitor of HAdV viral replication with antiviral activity that reduces lipid vacuolization in adipocytes, inhibits proliferation and decreases telomerase activity in human glioblastoma cells.

  • Telomerase-IN-2

    Telomerase-IN-2 shows potent inhibitory activity against telomerase by decreasing the expression of dyskerin (IC50: 0.89?μM).